Psiuk Dominika, Nowak Emilia, Cholewa Krystian, Łopuszańska Urszula, Samardakiewicz Marzena
Chair and Department of Psychology, Medical University of Lublin, 20-093 Lublin, Poland.
Life (Basel). 2021 Jul 29;11(8):765. doi: 10.3390/life11080765.
Due to an increasing number of depression diagnoses and limited effective treatments, researchers continue to explore novel therapeutic strategies for this disorder. Recently, interest has revolved around the use of serotonergic psychedelics to reduce the symptoms of depression. In this systematic review, we summarize the currently available knowledge on the safety and efficacy of psychedelic substances for the treatment of depression. A literature search of the PubMed/MEDLINE database identified 14 clinical trials from the last 10 years that examined the use of psilocybin, MDMA, DMT, or LSD for the treatment of depression symptoms. Some psychedelics, especially psilocybin, demonstrated an ability to reduce depressive symptoms as measured by several psychological scales, which was often sustained for months after the last psychedelic session. Moreover, one study revealed that psilocybin has comparable efficacy to escitalopram in the treatment of depression. None of the studies reported any serious adverse events associated with psychedelic administration. The reviewed studies suggest that psychedelics have great potential in depression therapy and, after addressing and overcoming the current study limitations, may be used as a novel method of treating depression in the future.
由于抑郁症诊断数量不断增加且有效治疗方法有限，研究人员继续探索针对这种疾病的新型治疗策略。最近，人们的兴趣集中在使用血清素能迷幻药来减轻抑郁症状。在本系统评价中，我们总结了目前关于迷幻物质治疗抑郁症的安全性和有效性的现有知识。对PubMed/MEDLINE数据库进行文献检索，确定了过去10年中14项临床试验，这些试验研究了裸盖菇素、摇头丸、二甲基色胺或麦角酸二乙酰胺用于治疗抑郁症状的情况。一些迷幻药，尤其是裸盖菇素，通过几种心理量表测量显示出减轻抑郁症状的能力，这种效果在上次服用迷幻药后的几个月内通常持续存在。此外，一项研究表明，裸盖菇素在治疗抑郁症方面与艾司西酞普兰具有相当的疗效。没有一项研究报告与使用迷幻药相关的任何严重不良事件。所审查的研究表明，迷幻药在抑郁症治疗方面具有巨大潜力，在解决和克服当前研究局限性之后，未来可能会被用作治疗抑郁症的一种新方法。
